PET in multiple sclerosis

Clinical Nuclear Medicine

Volumn 40, Issue 1, 2015, Pages e46-e52

  Niccolini, Flavia ^a,b   Su, Paul ^a   Politis, Marios ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Molecular imaging; Multiple sclerosis; PET

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABINOID; CARBON 11; CARRIER PROTEIN; FLUMAZENIL C 11; FLUORINE 18; MYELIN; RADIOLIGAND;

ARTICLE; BRAIN CELL; BRAIN METABOLISM; CELL ACTIVATION; DEMYELINATION; GABAERGIC SYSTEM; HUMAN; IMMUNE RESPONSE; MICROGLIA; MOLECULAR IMAGING; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REMYELINIZATION; METABOLISM; PATHOLOGY; SCINTISCANNING;

HUMANS; MULTIPLE SCLEROSIS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84917708943     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000359     Document Type: Article

References (78)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
3. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6:903-912.
4. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-269.
5. Kiferle L, Politis M, Muraro PA, et al. PET imaging in multiple sclerosisV current status and future applications. Eur J Neurol. 2011;18:226-231.
6. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312-318.
7. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem. 2007;14:1189-1197.
8. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119-145.
9. Suzumura A, Sawada M, Marunouchi T. Selective induction of interleukin-6 in mouse microglia by granulocyte-macrophage colony-stimulating factor. Brain Res. 1996;713:192-198.
10. Hartlage-Rübsamen M, Lemke R, Schliebs R. Interleukin-1beta, inducible nitric oxide synthase, and nuclear factor-kappa B are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/interferongamma injection. J Neurosci Res. 1999;57:388-398.
11. Floden AM, Li S, Combs CK. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci. 2005;25:2566-2575.
12. Banati RB. Visualising microglial activation in vivo. Glia. 2002;40:206-217.
13. Wilms H, Claasen J, Röhl C, et al. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis. 2003;14:417-424.
14. Benavides J, Cornu P, Dennis T, et al. Imaging of human brain lesions with an omega 3 site radioligand. Ann Neurol. 1988;24:708-712.
15. Banati RB, Goerres GW, Myers R, et al. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology. 1999;53:2199-2203.
16. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000;123:2321-2337.
17. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl). 1997;75:165-173.
18. Debruyne JC, Versijpt J, Van Laere KJ, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. 2003;10: 257-264.
19. Versijpt J, Debruyne JC, Van Laere KJ, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler. 2005;11:127-134.
20. Peterson JW, Bö L,Mörk S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389-400.
21. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128: 2705-2712.
22. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008;7:841-851.
23. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477-493.
24. Politis M, Gianneti P, Su P, et al. Increased PK11195 PET binding in the cortex of MS patients correlates with disability. Neurology. 2012;79:523-530.
25. Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259:1199-1205.
26. Politis M, Giannetti P, Niccolini F, et al. Decreased microglial activation precedes stabilization of disability in multiple sclerosis patients treated with natalizumab. Neurology. 2013;80(Meeting Abstracts 1):S21. 004
27. Rasmussen S, Wang Y, Kivisäkk P, et al. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsingVremitting experimental autoimmune encephalomyelitis. Brain. 2007;130:2816-2829.
28. Heppner FL, Greter M, Marino D, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med. 2005;11:146-152.
29. Vas A, Shchukin Y, Karrenbauer VD, et al. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. J Neurol Sci. 2008;264:9-17.
30. Oh U, Fujita M, Ikonomidou VN, et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol. 2011; 6:354-361.
31. Fujita M, Imaizumi M, Zoghbi SS, et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage. 2008;40:43-52.
32. Ikoma Y, Yasuno F, Ito H, et al. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. J Cereb Blood Flow Metab. 2007;27:173-184.
33. Chauveau F, Boutin H, Van Camp N, et al. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35:2304-2319.
34. Yasuno F, Ota M, Kosaka J, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008;64:835-841.
35. Petit-Taboué MC, Baron JC, Barré L, et al. Brain kinetics and specific binding of [11C]PK 11195 to omega 3 sites in baboons: positron emission tomography study. Eur J Pharmacol. 1991;200:347-351.
36. Boutin H, Chauveau F, Thominiaux C, et al. In vivo imaging of brain lesions with [(11)C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors. Glia. 2007;55:1459-1468.
37. Jučaite A, Cselényi Z, Arvidsson A, et al. Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brainVa PET study in control subjects. EJNMMI Res. 2012;2:15.
38. Cosenza-Nashat M, Zhao ML, Suh HS, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2008;35:306-328.
39. 18F]PBR111 binding is increate in lesional and perilesional white matter of MS patients. J Nucl Med. 2013;54:82.
40. Wu C, Tian D, Feng Y, et al. A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem. 2006;54:997-1004.
41. Wu C, Wei J, Tian D, et al. Molecular probes for imaging myelinated white matter in CNS. J Med Chem. 2008;51:6682-6688.
42. Wang Y, Wu C, Caprariello AV, et al. In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosci. 2009;29:14663-14669.
43. 11C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011; 69:673-680.
44. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab. 1981;1:7-36.
45. Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res. 1999;24:321-329.
46. Pozzilli C, Fieschi C, Perani D, et al. Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. J Neurol Sci. 1992;112:51-57.
47. Paulesu E, Perani D, Fazio F, et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage. 1996;4:87-96.
48. Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology. 1997;48:1566-1571.
49. Blinkenberg M, Jensen CV, Holm S, et al. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology. 1999;53:149-153.
50. Blinkenberg M, Mathiesen HK, Tscherning T, et al. Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. Neurol Res. 2012;34:52-58.
51. Sun X, Tanaka M, Kondo S, et al. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med. 1998;12:89-94.
52. Xu H, Cheng CL, Chen M, et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol. 2007;82:532-541.
53. Facchinetti F, Del Giudice E, Furegato S, et al. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia. 2003;41:161-168.
54. Docagne F, Mestre L, Loría F, et al. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets. 2008;12:185-195.
55. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 2001;356:381-408.
56. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54-61.
57. Carlisle SJ, Marciano-Cabral F, Staab A, et al. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol. 2002;2:69-82.
58. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003;126(Pt 10):2191-2202.
59. Maresz K, Carrier EJ, Ponomarev ED, et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005;95:437-445.
60. Fernández-Ruiz J, Pazos MR, García-Arencibia M, et al. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol. 2008;286: S91-S96.
61. Benito C, Romero JP, Tolón RM, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007;27:2396-2402.
62. Horti AG, Fan H, Kuwabara H, et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med. 2006;47:1689-1696.
63. Yasuno F, Brown AK, Zoghbi SS, et al. The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology. 2008;33:259-269.
64. Terry GE, Liow JS, Zoghbi SS, et al. Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage. 2009;48:362-370.
65. Sanabria-Bohórquez SM, Hamill TG, Goffin K, et al. Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur J Nucl Med Mol Imaging. 2010;37:920-933.
66. Finnema SJ, Donohue SR, Zoghbi SS, et al. Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo. Synapse. 2009;63:22-30.
67. Evens N, Muccioli GG, Houbrechts N, et al. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging. Nucl Med Biol. 2009;36:455-465.
68. Horti AG, Gao Y, Ravert HT, et al. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem. 2010;18:5202-5207.
69. Ahmad R, Koole M, Evens N, et al. Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects. Mol Imaging Biol. 2013;15:384-390.
70. Lloyd CM, Richardson MP, Brooks DJ, et al. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain. 2000; 123:2289-2296.
71. Murai H, Kiyosawa M, Suzuki Y, et al. A case of multiple sclerosis with homonymous hemianopia examined by positron emission tomography. Jpn J Ophthalmol. 2004;48:591-593.
72. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916-920.
73. Blackburn MR, Vance CO, Morschl E, et al. Adenosine receptors and inflammation. Handb Exp Pharmacol. 2009;193:215-269.
74. Mayne M, Shepel PN, Jiang Y, et al. Dysregulation of adenosine A1 receptormediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol. 1999;45:633-639.
75. Mayne M, Fotheringham J, Yan HJ, et al. Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol. 2001;49:727-735.
76. Mills JH, Thompson LF, Mueller C, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008;105:9325-9330.
77. Rissanen E, Virta J, Helin S, et al. Increased adenosine A2A-receptor binding in the brain of progressive multiple sclerosis patients detected using [11C]TMSX-PET. J Cereb Blood Flow Metab. 2013;33:1394-1401.
78. Sosnovik DE, Weissleder R. Emerging concepts in molecular MRI. Curr Opin Biotechnol. 2007;18:4-10.